A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

The requested reference [ab0f2c2ba8c45279362865774b8ba7f8443e23f7] no longer exists in our database. It has been replaced by the current reference: [2a7e2d014b8cead1f6b329ad4774696b3f381bee]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2011
The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of relapsing remitting multiple sclerosis, comparing two doses versus placebo.
Epistemonikos ID: ee88247f4cbf95492c2847c9dee5c525471784f1
First added on: Mar 31, 2022